CTUK - CT PROGRESSIVE INCOME PLC

Portfolio Update

· RNS

Summary

As of 30 Sep 2025 the trust’s top ten holdings total 48.4% (largest: OSB 7.3%, ICG 6.3%, AstraZeneca 5.7%) with sector exposure skewed to Financials 32.4%, Consumer Discretionary 12.5% and Health Care 10.9%; net gearing is 3.5%. Heavy financials and near-50% top-ten concentration increase sensitivity to UK interest rates, credit and single-stock/sector risk, while holdings in healthcare, staples and modest leverage provide some defensive ballast but limit upside from gearing.

Announcement

RNS Number : 2163E
CT UK Capital and Income Investment
21 October 2025
 

CT UK CAPITAL AND INCOME INVESTMENT TRUST PLC

 

Legal Entity Identifier: 21380052ETTRKV2A6Y19

 

 

All data as at 30 September 2025   

 

This data will shortly be available on the Company's website ctcapitalandincome.co.uk

Top Ten Holdings

%

OSB Group

7.3

ICG

6.3

AstraZeneca

5.7

Beazley

4.9

Unilever

4.9

RELX

4.8

LondonMetric Property

4.1

Legal & General Group

3.7

Rio Tinto

3.5

Shell

3.2

Total

48.4

 

Sector Breakdown

%

Financials

32.4

Consumer Discretionary

12.5

Health Care

10.9

Industrials

9.7

Consumer Staples

7.0

Real Estate

5.8

Technology

5.6

Utilities

5.3

Energy

5.2

Basic Materials

3.5

Telecommunications

2.1

Total

100.0

 

Note: All percentages are based on Gross Assets

 

Net Gearing

3.5%

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PFUVFLBLEBLXFBD